Celltrion’s Remsima announces dismissal of issuing ban suit of additional indication
Celltrion has started to enlarge its share in the Canadian market. On the 13th, Celltrion announced dismissal of the suit filed by Janssen to the Canadian court last September in regards to issuing ban of addition indication of inflammatory bowel disease(IBD) on Remsima(local name: Inflectra).
C...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
